Institutional investors buy 12.7M Aclaris (ACRS) shares for $39.8M

Rhea-AI Filing Summary

Aclaris Therapeutics, Inc. reported that from March 2–9, 2026 it sold 12.7 million shares of its common stock through its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.

These sales generated aggregate gross proceeds of $39.8 million and the shares were purchased by institutional investors, including Deep Track Capital. The disclosure is provided under Regulation FD and is expressly not deemed filed for liability purposes under Section 18 of the Exchange Act.

Insights

Equity Capital Markets Analyst

Aclaris raised $39.8M via ATM stock sales to institutional buyers.

Aclaris Therapeutics sold 12.7 million common shares for aggregate gross proceeds of $39.8 million under its amended and restated sales agreement with Leerink Partners and Cantor Fitzgerald. This reflects active use of an at-the-market style program to access equity capital.

The shares were purchased by institutional investors, including Deep Track Capital, indicating participation from professional investors. The disclosure is furnished under Regulation FD, so it is designed to keep the market informed rather than change existing registration terms.

Actual effects for shareholders depend on how this additional equity interacts with Aclaris’s broader capital structure and future updates in periodic reports covering the period including March 9, 2026.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Understanding 8-K Material Events →

0001557746false00015577462026-03-092026-03-09

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): March 9, 2026

​

​

Aclaris Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

​

​	​	​	​	​
Delaware	​	001-37581	​	46-0571712
(State or other jurisdiction of incorporation)	​	(Commission File Number)	​	(IRS Employer Identification No.)

​

701 Lee Road, Suite 103

Wayne, PA 19087

(Address of principal executive offices, including zip code)

​

(484) 324-7933

(Registrant’s telephone number, including area code)

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act: 

​

Title of Each Class:	​ ​ ​	Trading Symbol(s)	​ ​ ​	Name of Each Exchange on which Registered
Common Stock, $0.00001 par value		ACRS		The Nasdaq Stock Market, LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 7.01 Regulation FD Disclosure.

From March 2, 2026 through March 9, 2026, Aclaris Therapeutics, Inc. (the “Company”) sold 12.7 million shares of its common stock, for aggregate gross proceeds of $39.8 million pursuant to the Company’s amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. (the “Agents”) dated February 27, 2025. The Agents have informed the Company that the shares were purchased by institutional investors including Deep Track Capital.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company’s filings under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	ACLARIS THERAPEUTICS, INC.
​	​	​
​	By:	/s/ Kevin Balthaser
Date: March 9, 2026	​	Kevin Balthaser
​	​	Chief Financial Officer

​

​

3

FAQ

What equity transaction did Aclaris Therapeutics (ACRS) disclose in this 8-K?

Aclaris Therapeutics disclosed it sold 12.7 million shares of common stock, generating $39.8 million in aggregate gross proceeds. The sales were made under its amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co.

Over what period did Aclaris Therapeutics (ACRS) sell the 12.7 million shares?

The company sold 12.7 million shares of its common stock from March 2, 2026 through March 9, 2026. This specific one-week window is identified as the timeframe during which the at-the-market sales occurred under the existing sales agreement.

How much cash did Aclaris Therapeutics (ACRS) raise from the recent share sales?

The share sales produced aggregate gross proceeds of $39.8 million. This figure represents the total amount received before any fees or expenses associated with the company’s amended and restated sales agreement with Leerink Partners and Cantor Fitzgerald.

Who bought the newly sold Aclaris Therapeutics (ACRS) shares?

According to the disclosure, the shares were bought by institutional investors, including Deep Track Capital. The company notes that this information was provided by the sales agents involved in executing the transactions under the amended and restated sales agreement.

Under what agreement did Aclaris Therapeutics (ACRS) conduct these stock sales?

The sales were made pursuant to an amended and restated sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co. This agreement, dated February 27, 2025, governs how Aclaris can sell its common stock through those agents.

How is the Aclaris Therapeutics (ACRS) disclosure treated under securities law?

The company states this information is furnished under Item 7.01 Regulation FD Disclosure and is not deemed “filed” for Section 18 liability purposes. It is also not automatically incorporated by reference into other Securities Act or Exchange Act filings.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 EX-101.SCH 2.6 KB
• EX-101 EX-101.LAB 15.5 KB
• EX-101 EX-101.PRE 10.0 KB